Numinus Wellness Inc. (NUMI.TO)
| Previous Close | 0.0750 |
| Open | 0.0750 |
| Bid | 0.0700 x N/A |
| Ask | 0.0750 x N/A |
| Day's Range | 0.0700 - 0.0750 |
| 52 Week Range | 0.0650 - 0.2750 |
| Volume | |
| Avg. Volume | 702,374 |
| Market Cap | 24.041M |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a leader in mental health care specializing in innovative and evidence-based treatments, announces a strategic plan designed to streamline expenses and sharpen the company's focus on its higher-growth U.S. operations. This initiative is designed to enhance its U.S. wellness clinics and clinical research facilities and expand visibility and enrollment in its practitioner training program. Additionally, the plan support
- CNW Group
Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").
- PR Newswire
Numinus Wellness Provides Corporate Update
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention.
